Chongqing Lummy Pharmaceutical Hits Day Low Amid Price Pressure at CNY 4.56

Chongqing Lummy Pharmaceutical Co., Ltd. experienced a significant decline today, with the stock dropping by 8.98% and reaching an intraday low of CNY 4.56. This performance stands in contrast to the China Shanghai Composite, which fell by 3.05% on the same day. Over the past week, Chongqing Lummy has seen a decrease of 5.98%, while its one-month performance reflects a decline of 8.25%. Year-to-date, the stock has lost 11.28%, and its one-year performance shows a notable drop of 8.43%. In the longer term, the company has faced challenges, with a five-year performance decline of 42.28% and a staggering 49.95% drop over the past decade. Financial metrics indicate ongoing difficulties, including a negative net worth and a low return on capital employed (ROCE) of 0%. The company has reported losses for six consecutive quarters, with a net profit of CNY -103.8 million and an operating cash flow of CNY 70 million. These factors contribute to a challenging market position for Chongqing Lummy in the pharmaceuticals and biotechnology sector.